BRIEF-Mineralys Therapeutics Announces Positive Topline Results From Launch-HTN And Advance-HTN Pivotal Trials Of Lorundrostat For The Treatment Of Uncontrolled Or Resistant Hypertension

Reuters

10 Mar

BRIEF-Mineralys <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Positive Topline Results From Launch-HTN And Advance-HTN Pivotal Trials Of Lorundrostat For The Treatment Of Uncontrolled Or Resistant Hypertension

March 10 (Reuters) - Mineralys Therapeutics Inc MLYS.O:

MINERALYS THERAPEUTICS ANNOUNCES POSITIVE TOPLINE RESULTS FROM LAUNCH-HTN AND ADVANCE-HTN PIVOTAL TRIALS OF LORUNDROSTAT FOR THE TREATMENT OF UNCONTROLLED OR RESISTANT HYPERTENSION
MINERALYS THERAPEUTICS INC: ADVANCE-HTN MET ITS PRIMARY ENDPOINT
MINERALYS THERAPEUTICS INC: LAUNCH-HTN MET ITS PRIMARY ENDPOINT
MINERALYS THERAPEUTICS INC: LAUNCH-HTN MET ITS PRIMARY ENDPOINT
MINERALYS THERAPEUTICS INC: LORUNDROSTAT DEMONSTRATED A FAVORABLE SAFETY AND TOLERABILITY PROFILE IN BOTH PIVOTAL TRIALS

Source text: ID:nGNX7jhzJS

Further company coverage: MLYS.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.tigerhkgo.com/news/2518410232"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2518410232\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2518410232?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-10 19:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2518410232","market":"us","top_or_hot":-1,"title":"BRIEF-Mineralys Therapeutics Announces Positive Topline Results From Launch-HTN And Advance-HTN Pivotal Trials Of Lorundrostat For The Treatment Of Uncontrolled Or Resistant Hypertension","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Mineralys <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Positive Topline Results From Launch-HTN And Advance-HTN Pivotal Trials Of Lorundrostat For The Treatment Of Uncontrolled Or Resistant Hypertension</title></head><body><p><span>March 10 (Reuters)</span><span> - </span>Mineralys Therapeutics Inc <span>MLYS.O</span>:</p><ul><li><p>MINERALYS THERAPEUTICS ANNOUNCES POSITIVE TOPLINE RESULTS FROM LAUNCH-HTN AND ADVANCE-HTN PIVOTAL TRIALS OF LORUNDROSTAT FOR THE TREATMENT OF UNCONTROLLED OR RESISTANT HYPERTENSION</p></li><li><p>MINERALYS THERAPEUTICS INC: ADVANCE-HTN MET ITS PRIMARY ENDPOINT</p></li><li><p>MINERALYS THERAPEUTICS INC: LAUNCH-HTN MET ITS PRIMARY ENDPOINT</p></li><li><p>MINERALYS THERAPEUTICS INC: LAUNCH-HTN MET ITS PRIMARY ENDPOINT</p></li><li><p>MINERALYS THERAPEUTICS INC: LORUNDROSTAT DEMONSTRATED A FAVORABLE SAFETY AND TOLERABILITY PROFILE IN BOTH PIVOTAL TRIALS</p></li></ul><p>Source text: <span>ID:nGNX7jhzJS</span></p><p>Further company coverage: <span>MLYS.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Mineralys Therapeutics Announces Positive Topline Results From Launch-HTN And Advance-HTN Pivotal Trials Of Lorundrostat For The Treatment Of Uncontrolled Or Resistant Hypertension</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Mineralys Therapeutics Announces Positive Topline Results From Launch-HTN And Advance-HTN Pivotal Trials Of Lorundrostat For The Treatment Of Uncontrolled Or Resistant Hypertension\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-03-10 19:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Mineralys <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Positive Topline Results From Launch-HTN And Advance-HTN Pivotal Trials Of Lorundrostat For The Treatment Of Uncontrolled Or Resistant Hypertension</title></head><body><p><span>March 10 (Reuters)</span><span> - </span>Mineralys Therapeutics Inc <span>MLYS.O</span>:</p><ul><li><p>MINERALYS THERAPEUTICS ANNOUNCES POSITIVE TOPLINE RESULTS FROM LAUNCH-HTN AND ADVANCE-HTN PIVOTAL TRIALS OF LORUNDROSTAT FOR THE TREATMENT OF UNCONTROLLED OR RESISTANT HYPERTENSION</p></li><li><p>MINERALYS THERAPEUTICS INC: ADVANCE-HTN MET ITS PRIMARY ENDPOINT</p></li><li><p>MINERALYS THERAPEUTICS INC: LAUNCH-HTN MET ITS PRIMARY ENDPOINT</p></li><li><p>MINERALYS THERAPEUTICS INC: LAUNCH-HTN MET ITS PRIMARY ENDPOINT</p></li><li><p>MINERALYS THERAPEUTICS INC: LORUNDROSTAT DEMONSTRATED A FAVORABLE SAFETY AND TOLERABILITY PROFILE IN BOTH PIVOTAL TRIALS</p></li></ul><p>Source text: <span>ID:nGNX7jhzJS</span></p><p>Further company coverage: <span>MLYS.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MLYS","symbol_name":"Mineralys Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nFWN3PT0JY:1","article_id":"2518410232","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2518410232","pubTimestamp":1741604522,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Mineralys Therapeutics Announces Positive Topline Results From Launch-HTN And Advance-HTN Pivotal Trials Of Lorundrostat For The Treatment Of Uncontrolled Or Resistant HypertensionMarch 10 (Reut","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MLYS":"Mineralys Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"简介-Mineralys Therapeutics宣布Lorundrostat治疗不受控制或难治性高血压的Launch-HTN和Advance-HTN关键试验取得积极的顶线结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MLYS":0.9},"content_text":"BRIEF-Mineralys Therapeutics Announces Positive Topline Results From Launch-HTN And Advance-HTN Pivotal Trials Of Lorundrostat For The Treatment Of Uncontrolled Or Resistant HypertensionMarch 10 (Reuters) - Mineralys Therapeutics Inc MLYS.O:MINERALYS THERAPEUTICS ANNOUNCES POSITIVE TOPLINE RESULTS FROM LAUNCH-HTN AND ADVANCE-HTN PIVOTAL TRIALS OF LORUNDROSTAT FOR THE TREATMENT OF UNCONTROLLED OR RESISTANT HYPERTENSIONMINERALYS THERAPEUTICS INC: ADVANCE-HTN MET ITS PRIMARY ENDPOINTMINERALYS THERAPEUTICS INC: LAUNCH-HTN MET ITS PRIMARY ENDPOINTMINERALYS THERAPEUTICS INC: LAUNCH-HTN MET ITS PRIMARY ENDPOINTMINERALYS THERAPEUTICS INC: LORUNDROSTAT DEMONSTRATED A FAVORABLE SAFETY AND TOLERABILITY PROFILE IN BOTH PIVOTAL TRIALSSource text: ID:nGNX7jhzJSFurther company coverage: MLYS.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1}}}